The sale hints at profit-taking in a stock that’s executing operationally but facing tougher questions about durability and valuation.Aristotle Capital Boston disclosed in a November 14 SEC filing that it sold 503,122 shares of Supernus Pharmaceuticals (SUPN +0.25%), contributing to a reduction in its position by about $10.9 million.What HappenedAccording to a Securities and Exchange Commission (SEC) filing dated November 14, Aristotle Capital Boston reduced its holdings in Supernus Pharmaceuticals (SUPN +0 ...